InsidersTradesSigma
Ayala Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)
SEC:ayala-pharmaceuticals-inc-3f9050US·SEC (Form 4)Mcap 777.3Bn€Technology
Explore the full management transaction log of Ayala Pharmaceuticals, Inc., a publicly traded company based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Technology sector, Ayala Pharmaceuticals, Inc. has logged 3 reports. Market capitalisation: €777.3bn. The latest transaction was disclosed on 16 May 2022 — Attribution. Among the most active insiders: Mamluk Roni. All data is openly available.
3
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended August 2025 · cache
689.25 €
Analyst consensus
41 analystsStrong buy
249.00 €Target 584.24 €(-15%)1000.00 €
Income statement
Revenue37.38 Bn€
Gross profit14.87 Bn€40% margin
Net income8.54 Bn€41.5% margin
Valuation
PER (trailing)32.6x
PER (forward)6.7x
P/Book10.7x
Beta1.92
Balance sheet & cash
Market cap777.35 Bn€
Total debt15.28 Bn€
Free Cash Flow1.67 Bn€
Debt / Equity15%
Profitability & ownership
ROE39.8%
ROA20.1%
% insiders0.3%
% institutions81.1%
Last declaration on 16 May 2022
Declarations3 total
Executives◆Grant28SEC
0120,000 shares0
Common Stock
SEC:0000899243-22-018133:0·
Executives◆Grant25SEC
050,000 shares0
Common Stock
SEC:0000899243-22-018135:0·
Executives◆Grant17SEC
050,000 shares0
Common Stock
SEC:0000899243-22-018134:0·
3 of 3 declarations